EP1337255A4 - Use of p38 inhibitors for the treatment of inflammation-enhanced cough - Google Patents

Use of p38 inhibitors for the treatment of inflammation-enhanced cough

Info

Publication number
EP1337255A4
EP1337255A4 EP01997150A EP01997150A EP1337255A4 EP 1337255 A4 EP1337255 A4 EP 1337255A4 EP 01997150 A EP01997150 A EP 01997150A EP 01997150 A EP01997150 A EP 01997150A EP 1337255 A4 EP1337255 A4 EP 1337255A4
Authority
EP
European Patent Office
Prior art keywords
inflammation
inhibitors
treatment
enhanced cough
cough
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01997150A
Other languages
German (de)
French (fr)
Other versions
EP1337255A2 (en
Inventor
Don E Griswold
David C Underwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1337255A2 publication Critical patent/EP1337255A2/en
Publication of EP1337255A4 publication Critical patent/EP1337255A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP01997150A 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of inflammation-enhanced cough Withdrawn EP1337255A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24156400P 2000-10-19 2000-10-19
US241564P 2000-10-19
PCT/US2001/050629 WO2002060869A2 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of inflammation-enhanced cough

Publications (2)

Publication Number Publication Date
EP1337255A2 EP1337255A2 (en) 2003-08-27
EP1337255A4 true EP1337255A4 (en) 2006-01-25

Family

ID=22911205

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01997150A Withdrawn EP1337255A4 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of inflammation-enhanced cough

Country Status (4)

Country Link
EP (1) EP1337255A4 (en)
JP (1) JP2004530648A (en)
AU (1) AU2002248269A1 (en)
WO (1) WO2002060869A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1333833B1 (en) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases
BR0309053A (en) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compounds
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
JP2008535822A (en) 2005-03-25 2008-09-04 グラクソ グループ リミテッド New compounds
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
CN101495475A (en) 2005-03-25 2009-07-29 葛兰素集团有限公司 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
WO2006137421A1 (en) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. Agent for topical administration
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
MX2022001863A (en) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors.
TW202122082A (en) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
DK4084778T3 (en) 2019-12-30 2023-12-11 Deciphera Pharmaceuticals Llc AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USING THEREOF
KR20220123058A (en) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl ) -3-Phenylurea composition
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015164A1 (en) * 1997-09-23 1999-04-01 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
WO2001019322A2 (en) * 1999-09-17 2001-03-22 Smithkline Beecham Corporation Use of csaids in rhinovirus infection
WO2001038313A1 (en) * 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015164A1 (en) * 1997-09-23 1999-04-01 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
WO2001019322A2 (en) * 1999-09-17 2001-03-22 Smithkline Beecham Corporation Use of csaids in rhinovirus infection
WO2001038313A1 (en) * 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOEHM J C ET AL: "New inhibitors of p38 kinase", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 10, no. 1, 2000, pages 25 - 37, XP002259248, ISSN: 1354-3776 *
HASHIMOTO S ET AL: "P38 MAP KINASE REGULATES TNFALPHA, IL-1ALPHA- AND PAF-INDUCED RANTES AND GM-CSF PRODUCTION BY HUMAN BRONCHIAL EPTIHELIAL CELLS", CLINICAL AND EXPERIMENTAL ALLERGY, BLACKWELL SCIENTIFIC PUBLICATIONS, LONDON, GB, vol. 30, 2000, pages 48 - 55, XP002950812, ISSN: 0954-7894 *
UNDERWOOD DAVID C ET AL: "SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 293, no. 1, April 2000 (2000-04-01), pages 281 - 288, XP002355605, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
AU2002248269A1 (en) 2002-08-12
EP1337255A2 (en) 2003-08-27
WO2002060869A3 (en) 2003-01-03
JP2004530648A (en) 2004-10-07
WO2002060869A2 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
EP1337255A4 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
GB0025782D0 (en) Use of inhibitors
HK1061854A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1423120A4 (en) 2h-phthalazin-1-ones and methods for use thereof
AU6147401A (en) Compositions and methods for the treatment of cancer
IL152078A0 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
PL373301A1 (en) Phosphodiesterase 4 inhibitors
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU3408801A (en) Tnf-alpha inhibitors
EP1448218A4 (en) Beta-secretase inhibitors and methods of use
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU5464601A (en) Treatment of scale
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU8323701A (en) Inhibitors of p38
EP1442062A4 (en) Methods for the treatment of carcinoma
IL153971A0 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU2002231283A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
GB0008921D0 (en) Method of treatment
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis
EP1364653A4 (en) Casoase 3 inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030515

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/14 20000101ALI20051128BHEP

Ipc: A61P 29/00 20000101ALI20051128BHEP

Ipc: A61K 31/44 19850101ALI20051128BHEP

Ipc: A61K 31/50 19850101AFI20030707BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20051213

17Q First examination report despatched

Effective date: 20060922

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070205